Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.

MLA

Blin, Patrick, et al. “Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.” American Journal of Cardiovascular Drugs, vol. 20, no. 1, Feb. 2020, pp. 81–103. EBSCOhost, https://doi.org/10.1007/s40256-019-00359-z.

APA

Blin, P., Dureau-Pournin, C., Bénichou, J., Cottin, Y., Mismetti, P., Abouelfath, A., Lassalle, R., Droz, C., & Moore, N. (2020). Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS. American Journal of Cardiovascular Drugs, 20(1), 81–103. https://doi.org/10.1007/s40256-019-00359-z

Chicago

Blin, Patrick, Caroline Dureau-Pournin, Jacques Bénichou, Yves Cottin, Patrick Mismetti, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, and Nicholas Moore. 2020. “Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.” American Journal of Cardiovascular Drugs 20 (1): 81–103. doi:10.1007/s40256-019-00359-z.